These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17682218)

  • 1. [Prevention of hereditary breast cancer].
    Taguchi T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():610-4. PubMed ID: 17682218
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current perspective of chemoprevention in breast cancer].
    Asaga S; Jinno H; Sakata M; Kitajima M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():627-32. PubMed ID: 17682221
    [No Abstract]   [Full Text] [Related]  

  • 3. Twenty-five years of breast cancer risk models and their applications.
    Gail MH
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25722355
    [No Abstract]   [Full Text] [Related]  

  • 4. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
    Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
    Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer prevention in high-risk women: searching for new options.
    Nelson NJ
    J Natl Cancer Inst; 2011 May; 103(9):710-1. PubMed ID: 21515834
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prevention of familial breast cancers].
    Nomizu T; Ito K
    Nihon Rinsho; 2000 Apr; 58 Suppl():537-41. PubMed ID: 11026046
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
    Ingle JN; Liu M; Wickerham DL; Schaid DJ; Wang L; Mushiroda T; Kubo M; Costantino JP; Vogel VG; Paik S; Goetz MP; Ames MM; Jenkins GD; Batzler A; Carlson EE; Flockhart DA; Wolmark N; Nakamura Y; Weinshilboum RM
    Cancer Discov; 2013 Jul; 3(7):812-25. PubMed ID: 23764426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
    Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
    Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The breast cancer chemoprevention debate.
    Schmidt C
    J Natl Cancer Inst; 2011 Nov; 103(22):1646-7. PubMed ID: 22025628
    [No Abstract]   [Full Text] [Related]  

  • 11. Applying the Hippocratic Oath in breast cancer-The case for promoting prevention.
    Anampa JD; McEvoy MP; Feldman S; Sparano JA
    Breast J; 2019 Mar; 25(2):187-189. PubMed ID: 30834671
    [No Abstract]   [Full Text] [Related]  

  • 12. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.
    Eng-Wong J; Orzano-Birgani J; Chow CK; Venzon D; Yao J; Galbo CE; Zujewski JA; Prindiville S
    Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1696-701. PubMed ID: 18583470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
    O'Regan RM; Gajdos C; Dardes RC; De Los Reyes A; Park W; Rademaker AW; Jordan VC
    J Natl Cancer Inst; 2002 Feb; 94(4):274-83. PubMed ID: 11854389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer prevention in the era of precision medicine.
    Narod SA
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25855708
    [No Abstract]   [Full Text] [Related]  

  • 16. BRCA in breast cancer: ESMO Clinical Practice Guidelines.
    Balmaña J; Diez O; Rubio I; Castiglione M;
    Ann Oncol; 2010 May; 21 Suppl 5():v20-2. PubMed ID: 20555082
    [No Abstract]   [Full Text] [Related]  

  • 17. The prevention, detection, and management of breast cancer.
    Houssami N; Cuzick J; Dixon JM
    Med J Aust; 2006 Mar; 184(5):230-4. PubMed ID: 16515434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
    Gilbert FJ; Warren RM; Kwan-Lim G; Thompson DJ; Eeles RA; Evans DG; Leach MO;
    Radiology; 2009 Aug; 252(2):358-68. PubMed ID: 19703879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and management of hereditary breast cancer.
    Narod SA; Offit K
    J Clin Oncol; 2005 Mar; 23(8):1656-63. PubMed ID: 15755973
    [No Abstract]   [Full Text] [Related]  

  • 20. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.